Erectile dysfunction and its management in patients with diabetes mellitus
- 1 September 2015
- journal article
- Published by Springer Science and Business Media LLC in Reviews in Endocrine and Metabolic Disorders
- Vol. 16 (3), 213-231
- https://doi.org/10.1007/s11154-015-9321-4
Abstract
Diabetes can be described as a syndrome of multiple closely related conditions induced by a chronic state of hyperglycaemia resulting from defective insulin secretion, insulin action or both. Chronic complications associated with diabetes (including neuropathy, vascular disease, nephropathy and retinopathy) are common, and of these, erectile dysfunction (ED) deserves special attention. ED and its correlation with cardiovascular disease require careful evaluation and appropriate treatment. PDE5 inhibitors (PDE5is) are an important tool for the treatment of ED, with new drugs coming onto the market since the late 90s. This review offers an overview of PDE5is and their use in treating ED in diabetes. We underline the differences between different types of PDE5i, focusing on available doses, duration of action, T ½, side effects and selectivity profiles in relation to patients with diabetes. We also discuss the link between diabetes and ED in presence of various associated cofactors (obesity, hypertension and its pharmacological treatments, atherosclerosis, hyperhomocysteinaemia, neuropathy, nephropathy, hypogonadism and depression). Finally a number of past and ongoing clinical trials on the use of PDE5is in patients with diabetes are presented to offer an overview of the appropriate treatment of ED in this condition.Keywords
This publication has 134 references indexed in Scilit:
- Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes MellitusMayo Clinic Proceedings, 2012
- Erectile Dysfunction in Young Surgically Treated Patients With Lumbar Spine DiseaseSpine, 2012
- Erectile dysfunction and diabetes: A review of the current evidence-based medicine and a synthesis of the main available therapiesDiabetes & Metabolism, 2012
- Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 DiabetesJournal of Urology, 2011
- Cardioprotection with Postconditioning: Loss of Efficacy in Murine Models of Type-2 and Type-1 DiabetesAntioxidants and Redox Signaling, 2011
- Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetesDiabetes & Metabolism, 2009
- Improvement of vascular function by acute and chronic treatment with the PDE‐5 inhibitor sildenafil in experimental diabetes mellitusBritish Journal of Pharmacology, 2008
- Phimosis as a presenting feature of diabetesBJU International, 2007
- Infection induced inflammation is associated with erectile dysfunction in men with diabetesEuropean Journal of Clinical Investigation, 2006
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilThe New England Journal of Medicine, 1997